Log in

Relevant bibliographies by topics / Pharmaceutical polymorphism

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Pharmaceutical polymorphism'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical polymorphism.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical polymorphism"

1

Chistyakov, Dmitry, and Gleb Sergeev. "The Polymorphism of Drugs: New Approaches to the Synthesis of Nanostructured Polymorphs." Pharmaceutics 12, no. 1 (2020): 34. http://dx.doi.org/10.3390/pharmaceutics12010034.

Full text

Abstract:

Among the significant problems of modern pharmacology are the low solubility and bioavailability of drugs. One way to resolve this problem is to obtain new polymorphic forms of drugs with improved physicochemical properties. Various approaches have been developed with this aim, including the preparation of co-crystals, the use of nanoparticles, or the use of compounds in the form of a salt. A promising direction in pharmacology concerns the production of new stable polymorphic structures. In this mini-review, we consider certain aspects of drug polymorphism, methods for the synthesis of polymo

APA, Harvard, Vancouver, ISO, and other styles

2

Hean, Duane, Andreas Lemmerer, and Joseph Michael. "Rampant Polymorphism in Pharmaceuticals: An Isoniazid Derivative." Acta Crystallographica Section A Foundations and Advances 70, a1 (2014): C653. http://dx.doi.org/10.1107/s2053273314093462.

Full text

Abstract:

Investigations into the polymorphic forms of Active Pharmaceutical Ingredients (APIs) are of vital importance to drug formulations and are often kept a closely guarded secret by pharmaceutical companies. This secrecy is maintained as the nature of the polymorph could either make or break a drug formulation. Polymorphism is the ability of a solid crystalline form to exist in more than one structural arrangement. The variation in the crystalline forms often displays different mechanical, thermal, and chemical properties. These changes can remarkably influence the bioavailability, hygroscopicity,

APA, Harvard, Vancouver, ISO, and other styles

3

DELGADO, G., M. GUILLEN, and A. J. MORA. "4-METHYL HYPPURIC ACID: A CASE OF POLYMORPHISM AND SOLVATOMORPHISM." Periódico Tchê Química 16, no. 32 (2019): 812–19. http://dx.doi.org/10.52571/ptq.v16.n32.2019.830_periodico32_pgs_812_819.pdf.

Full text

Abstract:

Polymorphism is known as the ability of a solid material to exist in more than one form or crystal structure, with important applications in the preparation of active pharmaceutical ingredients. Characterization of different polymorphs of the specific metabolite of 4-xylene can contribute to the chemical and pharmaceutical industry. Polymorphism is of particular importance in industrial processes, where different physical properties of polymorphic forms can substantially alter the viability and quality of a manufactured product. This is particularly so for the design and production of drugs in

APA, Harvard, Vancouver, ISO, and other styles

4

Giordano, Ferdinando. "Polymorphism in pharmaceutical solids." Journal of Controlled Release 71, no. 3 (2001): 354–55. http://dx.doi.org/10.1016/s0168-3659(01)00252-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hudspeth, Jessica, Darren Goossens, and Richard Welberry. "Diffuse scattering in the polymorphs of p(N-methylbenzylidene)-p-methylaniline." Acta Crystallographica Section A Foundations and Advances 70, a1 (2014): C627. http://dx.doi.org/10.1107/s2053273314093723.

Full text

Abstract:

Polymorphism refers to the ability of a solid to exist in more than one crystal structure. Apart from being of scientific interest, it is of practical importance in the pharmaceutical and chemical manufacturing industries. In pharmaceuticals the polymorphic form of the substance can affect the ease of manufacture or the rate of uptake by the human body [1]. There is consequently a great need to be able to understand, predict and control polymorphism. This work is part of a larger study using diffuse scattering methods to investigate the role of molecular flexibility and disorder in polymorphis

APA, Harvard, Vancouver, ISO, and other styles

6

Kant, Rajni. "Pharmaceutical Drug Polymorphism: A Case Study of Three Novel Drugs." Acta Crystallographica Section A Foundations and Advances 70, a1 (2014): C544. http://dx.doi.org/10.1107/s2053273314094558.

Full text

Abstract:

Polymorphism is more widespread in pharmaceutical solids, with estimates of 30-50% in drug-like molecules, compared to 4-5% polymorphic crystals in the Cambridge Structural Database (Nangia, 2007). Most of the drug molecules are formulated and marketed in crystalline form and many of these are highly functionalized and can self-organize in several ways in the solid state with nearly the same lattice energies. Though a lot of work is going on in the field of pharmaceutical drug polymorphism and its possible application in the field of crystal engineering, yet there are difficulties in getting p

APA, Harvard, Vancouver, ISO, and other styles

7

Li, Z. G., R. L. Harlow, C. M. Foris, et al. "New Applications of Electron Diffraction in the Pharmaceutical Industry: Polymorph Determination by Using a Combination of Electron Diffraction and Synchrotron X-ray Powder Diffraction Techniques." Microscopy and Microanalysis 8, no. 2 (2002): 134–38. http://dx.doi.org/10.1017/s1431927601020050.

Full text

Abstract:

Electron diffraction has been recently used in the pharmaceutical industry to study the polymorphism in crystalline drug substances. While conventional X-ray diffraction patterns could not be used to determine the cell parameters of two forms of the microcrystalline GP IIb/IIIa receptor antagonist roxifiban, a combination of electron single-crystal and synchrotron powder diffraction techniques were able to clearly distinguish the two polymorphs. The unit-cell parameters of the two polymorphs were ultimately determined using new software routines designed to take advantage of each technique's u

APA, Harvard, Vancouver, ISO, and other styles

8

Ainurofiq, Ahmad, Kezia Esther Dinda, Maya Widia Pangestika, Ulia Himawati, Wening Dyah Wardhani, and Yustika Tamarin Sipahutar. "The effect of polymorphism on active pharmaceutical ingredients: A review." International Journal of Research in Pharmaceutical Sciences 11, no. 2 (2020): 1621–30. http://dx.doi.org/10.26452/ijrps.v11i2.2044.

Full text

Abstract:

Active pharmaceutical ingredients (API) are the main components in the production process of pharmaceutical products. If the API has a good quality, then it will lead to good pharmaceutical products. API consists of more than one different crystal form which, then forms a polymorph through the process of polymorphism. Until now, API polymorphism is still a big challenge in the pharmaceutical industry. That is because the nature of polymorphism is difficult to predict. One of them is by crystallizing molecules in one or many crystalline forms or combining with other molecules to form stable co-

APA, Harvard, Vancouver, ISO, and other styles

9

Karpinski, P. H. "Polymorphism of Active Pharmaceutical Ingredients." Chemical Engineering & Technology 29, no. 2 (2006): 233–37. http://dx.doi.org/10.1002/ceat.200500397.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fries, Aline Taís, Natália Olegário, Sarah Chagas Campanharo, Vitor Paulo Pereira, and Martin Steppe. "EVALUATION OF THE PRESENCE OF POLYMORPHIC FORMS AND INFLUENCE ON THE DISSOLUTION PROFILE OF TENOXICAM IN ACTIVE PHARMACEUTICAL INGREDIENT AND FORMULATIONS." Drug Analytical Research 2, no. 2 (2018): 27–36. http://dx.doi.org/10.22456/2527-2616.90005.

Full text

Abstract:

Polymorphism is a relatively common phenomenon among pharmaceutical compounds, and one of the main aspects to be considered in the production and development of medications. The investigation of polymorphism associated with oxicams, a group belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs) has increased in recent years and, in the case of tenoxicam, the existence of four polymorphic forms is reported in the literature. The objective of this study was to characterize the presence of different polymorphic forms of tenoxicam in active pharmaceutical ingredient and oral phar

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Pharmaceutical polymorphism"

1

Colli, Corrado. "Industrial crystallisation and polymorphism of active pharmaceutical ingredients." Thesis, Nottingham Trent University, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.442086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Abbas, Nasir. "An exploration of polymorphism in pharmaceutical compounds using high pressure." Thesis, University of Edinburgh, 2010. http://hdl.handle.net/1842/26512.

Full text

Abstract:

The effects of high pressure on a selection of organic compounds have been studied. Crystallisation at high pressure has been successfully used to grow a single crystal of an elusive polymorph (form II) of mefenamic acid. Milling experiments revealed that form I can be converted to form II by milling at both ambient temperature and at -78 °C. Direct compression of powder samples of form I at 1.5 GPa using methanol:ethanol as a pressure-transmitting medium resulted in the formation of a new high-pressure form III and this new form is recoverable to ambient pressure. Compression of powder sample

APA, Harvard, Vancouver, ISO, and other styles

3

Strachan, Clare, and n/a. "Spectroscopic investigation and quantitation of polymorphism and crystallinity of pharmaceutical compounds." University of Otago. School of Pharmacy, 2005. http://adt.otago.ac.nz./public/adt-NZDU20070427.141108.

Full text

Abstract:

Spectroscopy is increasingly used to investigate and monitor the solid state forms of pharmaceutical materials and products. Spectroscopy�s speed, nondestructive sampling, compatibility with fibre optics and safety also make it attractive for in-line monitoring. In this thesis, the spectroscopic techniques Fourier transform Raman spectroscopy, terahertz pulsed spectroscopy and second harmonic generation were used to characterise and quantify polymorphism and crystallinity of pharmaceutical compounds. Where possible, the multivariate analysis technique partial least squares was used for quant

APA, Harvard, Vancouver, ISO, and other styles

4

Campbell, Susan Christina. "Pharmaceutical polymorphism : an investigation using solid-state nuclear magnetic resonance spectroscopy." Thesis, Durham University, 1998. http://etheses.dur.ac.uk/5021/.

Full text

Abstract:

The study of two pharmaceutically active systems that each display polymorphism has provided a platform upon which to develop and apply solid-state NMR techniques in order to increase the understanding of the solid-state structure of small organic molecules. The multidisciplinary approach adopted has highlighted the advantages of solid-state NMR as a non-invasive probe of molecular conformation and crystallographic packing.Carbon-13 CP/MAS spectra of the two polymorphs of BRL55834 - a fluorinated benzopyran derivative - immediately suggest the presence of one and three molecules in the asymmet

APA, Harvard, Vancouver, ISO, and other styles

5

Cox, Jason R. "Controlling the Polymorphism of Active Pharmaceutical Ingredients with Two-Dimensional Templates." Digital WPI, 2009. https://digitalcommons.wpi.edu/etd-theses/362.

Full text

Abstract:

Self-assembled monolayers on gold and glass substrates are employed as templates to direct the crystal growth and polymorphism of active pharmaceutical ingredients. Orthogonal approaches are used to control polymorphism either through complementary hydrogen-bonding interactions or through repulsive interactions.

APA, Harvard, Vancouver, ISO, and other styles

6

Cox, Jason R. "Controlling the polymorphism of active pharmaceutical Iigredients with two-dimensional templates." Worcester, Mass. : Worcester Polytechnic Institute, 2009. http://www.wpi.edu/Pubs/ETD/Available/etd-042709-112211/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Austin, Talbir Kaur. "Hydration, polymorphism and disorder in organic solids, including materials of pharmaceutical relevance." Thesis, Cardiff University, 2006. http://orca.cf.ac.uk/56079/.

Full text

Abstract:

The studies described in this thesis are concerned with understanding and rationalising the inter-relationships between structural and other physical properties of organic solids encompassing hydrates, polymorphs and homologous series. This is achieved through assessment of the crystal packing arrangements and the nature of the intermolecular interactions, which may have a profound impact on the stability and physical properties of organic materials. Such an understanding is critically important when selecting or designing materials that demonstrate specific defined properties. The first part

APA, Harvard, Vancouver, ISO, and other styles

8

Slavin, Paul Anthony. "Crystallisation and polymorphism of the pharmaceutical indomethacin from simple and complex solvents." Thesis, University of Strathclyde, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273431.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

McMahon, Jennifer Anne. "Crystal engineering of novel pharmaceutical forms." [Tampa, Fla] : University of South Florida, 2006. http://purl.fcla.edu/usf/dc/et/SFE0001792.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Patel, Nirav D., Kanishka Chakraborty, Garrett Messmer, Koyamangalath Krishnan, and John B. Bossaer. "Severe Sunitinib-Induced Myelosuppression in a Patient with a CYP 3A4 Polymorphism." Digital Commons @ East Tennessee State University, 2017. https://dc.etsu.edu/etsu-works/2330.

Full text

Abstract:

Sunitinib, an oral vascular endothelial growth factor receptor, is a first-line option for metastatic renal cell carcinoma and widely used in clinical practice. Despite the proven benefit of sunitnib in metastatic renal cell carcinoma, patients may suffer from a variety of adverse events including hypertension, fatigue, hypothyroidism, hand?foot skin reactions, rash, depigmentation, and myelosuppression. Myelosuppression is usually mild, transient and resolves during the two weeks at the end of each cycle where no drug is taken. We present a case of severe and early grade 3 neutropenia and thr

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Pharmaceutical polymorphism"

1

Hilfiker, Rolf, and Markus von Raumer, eds. Polymorphism in the Pharmaceutical Industry. Wiley-VCH Verlag GmbH & Co. KGaA, 2018. http://dx.doi.org/10.1002/9783527697847.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

G, Brittain H., ed. Polymorphism of pharmaceutical solids. 2nd ed. Informa Healthcare, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Brittain, Harry G., ed. Polymorphism in Pharmaceutical Solids. CRC Press, 2018. http://dx.doi.org/10.3109/9781420073225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

G, Brittain H., ed. Polymorphism in pharmaceutical solids. M. Dekker, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hilfiker, Rolf. Polymorphism: In the Pharmaceutical Industry. Wiley & Sons, Limited, John, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hilfiker, Rolf. Polymorphism: In the Pharmaceutical Industry. Wiley & Sons, Incorporated, John, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hilfiker, Rolf. Polymorphism: In the Pharmaceutical Industry. Wiley-VCH, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rolf, Hilfiker, ed. Polymorphism in the pharmaceutical industry. Wiley-VCH, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Polymorphism of Pharmaceutical Solids, Second Edition (Drugs and the Pharmaceutical Sciences). 2nd ed. Informa Healthcare, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hilfiker, Rolf, and Markus von Raumer. Polymorphism in the Pharmaceutical Industry: Solid Form and Drug Development. Wiley & Sons, Incorporated, John, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Pharmaceutical polymorphism"

1

Carlton, Robert Allen. "Polymorphism." In Pharmaceutical Microscopy. Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-8831-7_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Reutzel-Edens, Susan M., and Ann W. Newman. "Physical Characterization of Hygroscopicity in Pharmaceutical Solids." In Polymorphism. Wiley-VCH Verlag GmbH & Co. KGaA, 2006. http://dx.doi.org/10.1002/3527607889.ch9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hilfiker, Rolf, Fritz Blatter, and Markus von Raumer. "Relevance of Solid-state Properties for Pharmaceutical Products." In Polymorphism. Wiley-VCH Verlag GmbH & Co. KGaA, 2006. http://dx.doi.org/10.1002/3527607889.ch1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chalmers, John M., and Geoffrey Dent. "Vibrational Spectroscopic Methods in Pharmaceutical Solid-state Characterization." In Polymorphism. Wiley-VCH Verlag GmbH & Co. KGaA, 2006. http://dx.doi.org/10.1002/3527607889.ch5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Miller, Stephen P. F., Andre S. Raw, and Lawrence X. Yu. "Scientific Considerations of Pharmaceutical Solid Polymorphism in Regulatory Applications." In Polymorphism. Wiley-VCH Verlag GmbH & Co. KGaA, 2006. http://dx.doi.org/10.1002/3527607889.ch15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Govindarajan, Ramprakash, and Raj Suryanarayanan. "Processing-induced Phase Transformations and Their Implications on Pharmaceutical Product Quality." In Polymorphism. Wiley-VCH Verlag GmbH & Co. KGaA, 2006. http://dx.doi.org/10.1002/3527607889.ch13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Nie, Haichen, and Stephen R. Byrn. "Polymorphism and Phase Transitions." In Pharmaceutical Crystals. John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781119046233.ch5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Nahler, Gerhard. "single nucleotide polymorphism." In Dictionary of Pharmaceutical Medicine. Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_1293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Reutzel-Edens, Susan M., Doris E. Braun, and Ann W. Newman. "Hygroscopicity and Hydrates in Pharmaceutical Solids." In Polymorphism in the Pharmaceutical Industry. Wiley-VCH Verlag GmbH & Co. KGaA, 2018. http://dx.doi.org/10.1002/9783527697847.ch6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

von Raumer, Markus, and Rolf Hilfiker. "Solid State and Polymorphism of the Drug Substance in the Context of Quality by Design and ICH Guidelines Q8-Q12." In Polymorphism in the Pharmaceutical Industry. Wiley-VCH Verlag GmbH & Co. KGaA, 2018. http://dx.doi.org/10.1002/9783527697847.ch1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical polymorphism"

1

Yang, Mingshi, Jukka Rantanen, Frans van den Berg, Paul Young, Jianxiong Wu, and Yan-Ying Lee. "Polymorphism of Spray-dried Mannitol as a Function of Particle Size: Effect of Ethanol." In The 1st Electronic Conference on Pharmaceutical Sciences. MDPI, 2011. http://dx.doi.org/10.3390/ecps2011-00530.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

DU, Yong, Yi XIA, Wenjian TANG, and Zhi HONG. "Characterization of Polymorphism in Sulfamethoxazole Pharmaceutical Molecule Using Terahertz Time-domain Spectroscopy." In Laser and Tera-Hertz Science and Technology. OSA, 2012. http://dx.doi.org/10.1364/ltst.2012.sth4a.07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mohara, Mizuki, Kenji Aiko, Kei Shimura, and Touya Ono. "Quantitative analysis and inspection for pharmaceutical polymorphism with injection-seeded terahertz parametric generation technique." In 2018 43rd International Conference on Infrared, Millimeter, and Terahertz Waves (IRMMW-THz 2018). IEEE, 2018. http://dx.doi.org/10.1109/irmmw-thz.2018.8510222.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Pajander, Jari, Alexia Rensonnet, Marin Øvergård, et al. "Polymorphic transition of carbamazepine during hot melt processing." In The 2nd Electronic Conference on Pharmaceutical Sciences. MDPI, 2012. http://dx.doi.org/10.3390/ecps2012-00815.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hermanto, Martin Wijaya, Richard D. Braatz, and Min-Sen Chiu. "Optimal Control of Polymorphic Transformation in Batch Pharmaceutical Crystallization." In 2007 IEEE 22nd International Symposium on Intelligent Control. IEEE, 2007. http://dx.doi.org/10.1109/isic.2007.4359795.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hermanto, Martin Wijaya, Richard D. Braatz, and Min-Sen Chiu. "Optimal Control of Polymorphic Transformation in Batch Pharmaceutical Crystallization." In 2007 IEEE International Conference on Control Applications. IEEE, 2007. http://dx.doi.org/10.1109/cca.2007.4389221.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hermanto, Martin Wijaya, Richard D. Braatz, and Min-Sen Chiu. "A run-to-run control strategy for polymorphic transformation in pharmaceutical crystallization." In 2006 IEEE Conference on Computer Aided Control System Design, 2006 IEEE International Conference on Control Applications, 2006 IEEE International Symposium on Intelligent Control. IEEE, 2006. http://dx.doi.org/10.1109/cacsd-cca-isic.2006.4776968.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hermanto, Martin, Richard Braatz, and Min-sen Chiu. "A Run-to-run Control Strategy for Polymorphic Transformation in Pharmaceutical Crystallization." In 2006 IEEE International Conference on Control Applications. IEEE, 2006. http://dx.doi.org/10.1109/cca.2006.286194.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hermanto, M. W., R. D. Braatz, and Min-Sen Chiu. "Run-to-run Temperature Control for Polymorphic Transformation in Pharmaceutical Crystallization with Uncertainties." In 2006 6th World Congress on Intelligent Control and Automation. IEEE, 2006. http://dx.doi.org/10.1109/wcica.2006.1714325.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!